Isis gets $3.5M as antisense drug trial proceeds

05/12/2013 | Genetic Engineering & Biotechnology News

Biogen Idec paid Isis Pharmaceuticals a $3.5 million milestone fee after the dosing of the first infant with spinal muscular atrophy in a midstage trial of the antisense drug ISIS-SMN. The open-label study, which will involve eight infants with the condition, will be carried out in the U.S. and Canada.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI